Cerevel Therapeutics (CERE) Stock Analysis

What Cerevel Therapeutics does

Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing treatments for a range of neuroscience disorders. The company boasts a robust pipeline of therapeutic candidates currently undergoing various phases of clinical evaluation. Key assets include emraclidine, a positive allosteric modulator (PAM) in Phase 1b trials for schizophrenia. Another PAM, Darigabat, is being assessed in a Phase 2 proof-of-concept study for drug-resistant focal onset seizures in epilepsy, as well as in a Phase 1 trial for acute anxiety. For Parkinson's disease, Cerevel is advancing Tavapadon, a selective dopamine D1/D5 partial agonist, through Phase 3 clinical trials for both early and late stages of the condition. A related compound, CVL-871, also a selective dopamine D1/D5 partial agonist, is in Phase 2a trials for dementia-related apathy. The company's portfolio further includes CVL-936, a selective dopamine D3-preferring antagonist in Phase I for substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist targeting major depressive disorder and substance use disorder; and CVL-047, a selective PDE4 inhibitor also aimed at major depressive disorder and substance use disorder. Beyond individual compounds, Cerevel is actively developing an M4 agonist program for psychosis and related indications, alongside an LRRK2 inhibitor program designed to address the progression of Parkinson's disease. Founded in 2018, Cerevel Therapeutics is headquartered in Cambridge, Massachusetts.

Key metrics

ETFs linked to CERE

Broad-market and Healthcare sector ETFs an investor holding Cerevel Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how CERE fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Cerevel Therapeutics?

Cerevel Therapeutics trades under the ticker CERE on NASDAQ.

Which exchange is CERE listed on?

CERE is listed on NASDAQ.

What sector does Cerevel Therapeutics operate in?

Cerevel Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze CERE in a portfolio?

PortView shows CERE's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.